Researchers are testing a new experimental treatment called UKK-0018 for adults with peanut allergy. The study aims to learn whether UKK-0018 is safe, how well people tolerate it, and whether it may help reduce allergic reactions to peanuts.
Peanut allergy can be serious and may cause life-threatening allergic reactions. There is currently no cure. UKK-0018 is a vaccine immunotherapy designed to help the body's immune system become less sensitive to peanuts over time.
Researchers want to understand whether this treatment is safe and whether it may reduce the severity of peanut allergy reactions. All participants in this study will receive UKK-0018 and will be closely monitored throughout the study.
Anticipated enrolment close date: 31 December 2027
Who can take part
You may be eligible to participate if you:
- are aged 18 to 55 years
- have a confirmed peanut allergy
- are generally healthy apart from your peanut allergy
- are willing to attend study visits and follow study requirements
You may not be eligible to participate if you:
- are pregnant or breastfeeding
What's involved
Participants may be involved in the study for up to 38 weeks. The study includes screening, treatment and follow-up periods. Participants may be asked to:
- attend up to 19 study visits, depending on their study group
- receive three injections of the study treatment (UKK-0018)
- have blood and urine tests
- have health checks including blood pressure, heart rate, temperature and breathing rate measured
- have heart monitoring (ECG) and skin prick allergy tests
- complete peanut food challenge tests under medical supervision
- complete questionnaires about how peanut allergy affects daily life
- participate in phone follow-up appointments between visits.